Spero Therapeutics
SPRO
88 hedge funds and large institutions have $244M invested in Spero Therapeutics in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 20 closing their positions.
84% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $711K
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.01% less ownership
Funds ownership: 62.88% → 58.87% (-4%)
6% less funds holding
Funds holding: 94 → 88 (-6)
11% less capital invested
Capital invested by funds: $273M → $244M (-$29M)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.38M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$701K |
| 3 |
JP Morgan Chase
New York
|
+$661K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$446K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$306K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.63M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.67M |
| 3 |
Goldman Sachs
New York
|
-$1.67M |
| 4 |
Morgan Stanley
New York
|
-$1.67M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$730K |
SPRO Hedge Fund Activity: Q2 2021 in Review
88 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2021, worth a combined $244M — down 11% from $273M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SPRO and 14 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 28 added.
The largest buyer was Vanguard Group, adding an estimated $2.38M. The largest seller was State Street, cutting an estimated $7.63M.
- 88 institutional investors held Spero Therapeutics (SPRO) as of Q2 2021, down from 94 in Q1 2021.
- Funds reported $244M of Spero Therapeutics stock for Q2 2021, down 11% quarter-over-quarter.
- 14 funds opened new Spero Therapeutics positions in Q2 2021 and 20 closed out, a net change of -6 holders.
- The largest Spero Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $2.38M added.
- The largest Spero Therapeutics seller in Q2 2021 was State Street, an estimated $7.63M sold.
Based on aggregated 13F filings for Q2 2021.